Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

INDUSTRY

Sponsor class

Stopped The study was discontinued early because the Sponsor de-prioritized development of mocetinostat. The decision to stop was not due to any patient safety issues.

Conditions

Advanced Cancer

Interventions

DRUG: Mocetinostat - 50 mg
DRUG: Mocetinostat - 70 mg
DRUG: Mocetinostat - 90 mg
DRUG: Mocetinostat - Recommended Phase 2 Dose (70 mg)
DRUG: Durvalumab - 1500 mg

Sponsor

Mirati Therapeutics Inc.